Abstract:Preclinical testing of treatments for postpartum depression (PPD) has been limited due to the lack of available animal models of such a complex disorder. To address this limitation, our laboratory has generated unique preclinical mouse models that exhibit abnormal postpartum behaviors. Mice with a loss or reduction in the expression of the GABAA receptor (GABAAR) δ subunit (Gabrd -/- or Gabrd +/-, respectively) and mice that lack the K+/Cl- co-transporter, KCC2, specifically in corticotropin-releasing hormone (CRH) neurons (KCC2/Crh mice) exhibit depression-like behaviors restricted to the postpartum period and deficits in maternal care, which serve as useful tools for testing novel therapeutic compounds. Utilizing these preclinical models, we tested the ability of a novel, synthetic, neuroactive steroid developed by SAGE Therapeutics, SGE-516, to improve abnormal postpartum behaviors. Gabrd -/-, Gabrd +/-, and KCC2/Crh dams treated with SGE-516 (450 mg/kg chow) during late pregnancy exhibit a decrease in depression-like behaviors and improvements in maternal care at 48 h postpartum. Interestingly, acute treatment with SGE-516 also exhibits robust therapeutic effects in these preclinical PPD models. We previously discovered abnormal stress reactivity associated with hypothalamic-pituitary-adrenal (HPA) axis dysregulation associated with depression-like behaviors in the preclinical PPD models, evident from an increase in stress-induced corticosterone levels and dephosphorylation and downregulation of KCC2 in the paraventricular nucleus of the hypothalamus (PVN) during the peripartum period. Here we demonstrated that SGE-516 treatment is sufficient to prevent the stress-induced increase in corticosterone and dephosphorylation and downregulation of KCC2 in the PVN. In contrast, and consistent with the distinct pharmacology of SGE-516 compared to benzodiazepines, treatment with clobazam (250 mg/kg chow) did not alter the depression-like phenotype or deficits in maternal care observed in these preclinical models of PPD. These findings are consistent with the positive double-blind, randomized, placebo-controlled trial findings of a similar compound, brexanolone, in the treatment of patients with postpartum depression. Further, these findings validate the use of these preclinical models of PPD for screening novel compounds for the treatment of postpartum depression.

Antidepressant-like effects of translocator protein (18 kDa) ligand ZBD-2 in mouse models of postpartum depression

Antidepressant-Like and Anxiolytic-Like Effects of ZBD-2, a Novel Ligand for the Translocator Protein (18 Kda).

Neuroprotective Effects of A Novel Translocator Protein (18 Kda) Ligand, Zbd-2, Against Focal Cerebral Ischemia and Nmda-Induced Neurotoxicity

Inhibition of Autophagy in Microglia Alters Depressive-Like Behavior Via BDNF Pathway in Postpartum Depression

Resveratrol Alleviates Postpartum Depression-Like Behavior by Activating Autophagy Via SIRT1 and Inhibiting AKT/mTOR Pathway.

Anxiolytic-like Effects of Translocator Protein (TSPO) Ligand ZBD-2 in an Animal Model of Chronic Pain

The 18 Kda Translocator Protein (TSPO) Overexpression in Hippocampal Dentate Gyrus Elicits Anxiolytic-Like Effects in a Mouse Model of Post-traumatic Stress Disorder

Progesterone and Fluoxetine treatments of postpartum depressive-like behavior in rat model.

Repeated Administration of AC-5216, a Ligand for the 18 Kda Translocator Protein, Improves Behavioral Deficits in a Mouse Model of Post-Traumatic Stress Disorder.

Paeoniflorin exhibits antidepressant activity in rats with postpartum depression via the TSPO and BDNF‑mTOR pathways

Overexpression of the 18 Kda Translocator Protein (TSPO) in the Hippocampal Dentate Gyrus Produced Anxiolytic and Antidepressant-Like Behavioural Effects.

Network pharmacology and molecular docking analysis on the mechanism of Baihe Zhimu decoction in the treatment of postpartum depression

Activation of σ-1 receptor mitigates estrogen withdrawal-induced anxiety/depressive-like behavior in mice via restoration of GABA/glutamate signaling and neuroplasticity in the hippocampus

Effect of Zbd-2 on Chronic Pain, Depressive-Like Behaviors, and Recovery of Motor Function Following Spinal Cord Injury in Mice

A Novel, Synthetic, Neuroactive Steroid Is Effective at Decreasing Depression-Like Behaviors and Improving Maternal Care in Preclinical Models of Postpartum Depression

Timosaponin B-III exhibits antidepressive activity in a mouse model of postpartum depression by the regulation of inflammatory cytokines, BNDF signaling and synaptic plasticity.

Brain neurotransmitters in an animal model with postpartum depressive-like behavior

Antidepressant Effects of 3-(3,4-methylenedioxy-5-trifluoromethyl Phenyl)-2E-propenoic Acid Isobutyl Amide Involve TSPO-mediated Mitophagy Signalling Pathway

Network Pharmacology and Transcriptomics to Explore the Pharmacological Mechanisms of 20(S)-Protopanaxatriol in the Treatment of Depression

Neurosteroids and translocator protein 18 kDa (TSPO) ligands as novel treatment options in depression

Changes of TSPO-mediated Mitophagy Signaling Pathway in Learned Helplessness Mice